Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Marina C Garassino, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Giovanna Speranza, Manuel Domine, Maximilian J Hochmair, Steven Powell, Susanna Yee-Shan Cheng, Helge G Bischoff, Nir Peled, Martin Reck, Rina Hui, Edward B Garon, Michael Boyer, Ziwen Wei, Thomas Burke, M Catherine Pietanza, Delvys Rodríguez-Abreu

The Lancet Oncology, March 2020

Abstract link